142 related articles for article (PubMed ID: 34273660)
1. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions.
Piotrowska M; Spodzieja M; Kuncewicz K; Rodziewicz-Motowidło S; Orlikowska M
Eur J Med Chem; 2021 Nov; 224():113694. PubMed ID: 34273660
[TBL] [Abstract][Full Text] [Related]
2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
3. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of CD160:HVEM Recognition.
Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
7. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
[TBL] [Abstract][Full Text] [Related]
8. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
9. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C; Speiser DE; Derré L; Olive D
Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
[TBL] [Abstract][Full Text] [Related]
10. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
11. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
Chibueze CE; Yoshimitsu M; Arima N
Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
[TBL] [Abstract][Full Text] [Related]
12. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes.
Meng Q; Zaidi AK; Sedy J; Bensussan A; Popkin DL
J Immunol; 2019 Apr; 202(7):2057-2068. PubMed ID: 30770415
[TBL] [Abstract][Full Text] [Related]
14. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
15. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
[TBL] [Abstract][Full Text] [Related]
16. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
17. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
[TBL] [Abstract][Full Text] [Related]
18. CD160: a unique activating NK cell receptor.
Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
[TBL] [Abstract][Full Text] [Related]
19. HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria.
Shui JW; Larange A; Kim G; Vela JL; Zahner S; Cheroutre H; Kronenberg M
Nature; 2012 Aug; 488(7410):222-5. PubMed ID: 22801499
[TBL] [Abstract][Full Text] [Related]
20. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A
Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
